EARLY LENZILUMAB TREATMENT OF COVID-19 PATIENTS USING C-REACTIVE PROTEIN AS A BIOMARKER IMPROVES EFFICACY: RESULTS FROM THE PHASE 3 ‘LIVE-AIR’ TRIAL

Zelalem Temesgen, Colleen F. Kelley, Franklin Cerasoli, Adrian Kilcoyne, Dale Chappell, Cameron Durrant, Omar Ahmed, Gabrielle Chappell, Victoria M. Catterson, Christopher Polk, Andrew D. Badley, Vincent C. Marconi, the LIVE-AIR Study Group
doi: https://doi.org/10.1101/2021.12.30.21267140

Data Availability

All data produced in the present work are contained in the manuscript

Back to top
Posted January 01, 2022.
Download PDF
Data/Code
Email
EARLY LENZILUMAB TREATMENT OF COVID-19 PATIENTS USING C-REACTIVE PROTEIN AS A BIOMARKER IMPROVES EFFICACY: RESULTS FROM THE PHASE 3 ‘LIVE-AIR’ TRIAL
Zelalem Temesgen, Colleen F. Kelley, Franklin Cerasoli, Adrian Kilcoyne, Dale Chappell, Cameron Durrant, Omar Ahmed, Gabrielle Chappell, Victoria M. Catterson, Christopher Polk, Andrew D. Badley, Vincent C. Marconi, the LIVE-AIR Study Group
medRxiv 2021.12.30.21267140; doi: https://doi.org/10.1101/2021.12.30.21267140
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area